(00:32)  Would you mind telling our listeners a little about yourself and your background? (01:16) This evaluation is about CIDP — chronic inflammatory demyelinating polyneuropathy, correct? (02:16) Can you give us an overview of what the CIDP evaluation will consist of? (04:38) Our standalone test for neurofascin-155 won't change, but will be rolled into this new test along with contactin-1, correct? (06:41) This is a very rare disease with subtle clues, so does it make logical sense to pair these two antibodies? (08:07) Why did we choose a cell-binding assay over a western blot or other methodology? Is there a reason why contactin-1 is better on CBA methodology? (09:40) Can you elaborate on what this phenotype-specific approach means for neurologists, and how it makes their ordering easier? (11:14) Even though it's hard to determine exactly what test to order for these patients, testing too broadly can just add to the confusion. Is a narrowed evaluation that answers specific questions more helpful? (14:42) Can you give us any clues as to when a physician shouldn't order this test because it's unlikely to be positive? (15:51) How does this test drive patient care? A lot of these patients are therapy refractory. What would be the second- or third-level treatment? Is there any oncological association with antibody positivity? (18:44) Are there any alternative options for diagnostic answers for this challenging patient population? (20:44) What is the key takeaway? What excites you most about this new test launch?

Ver todos los episodios